HDAC9 and leukemia: Although the enhancement of the cytotoxicity of FLT3 inhibitors with HDAC inhibitor dacinostat was registered for MV-4-11 cells and primary leukemia cells, this effect was specific for AML cells harboring FLT3 activating mutation [57].